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INTRODUCTION: Spontaneous healing of 
cartilage injuries is poor. Untreated cartilage 
defects are associated with pain and disability, and 
predispose to osteoarthritis. Current therapies, 
including innovative autologous cell-based 
treatments (exclusively based on articular 
chondrocytes), cannot predictably and 
reproducibly restore cartilage structure and 
function1. Based on several years of basic and pre-
clinical research supporting the use of nasal 
chondrocytes as a suitable cell source for the 
regeneration of native cartilage, different clinical 
trials have been initiated by our group.  
METHODS & RESULTS: Autologous nasal 
chondrocytes are isolated from a small nasal 
septum cartilage biopsy harvested in minimally 
invasive out-patient procedure. Nasal chondrocytes 
are expanded in vitro and then cultured onto a 
collagen membrane in chondrogenic medium to 
promote the deposition of abundant extracellular 
matrix (Fig. 1).  
 
Fig. 1: Macroscopic (A) and histological (B, 
Safranin-O) picture of tissue engineered cartilage 
graft based on nasal chondrocytes.  
In a Phase I clinical trial, tissue-engineered 
cartilage grafts were used for the reconstruction of 
nasal alar lobules, leading to a durable and stable 
repair with restoration of function and 
aesthetically satisfactory outcomes2. Based on 
subsequent in vitro and pre-clinical studies, a 
further Phase I clinical trial was conducted in 
which autologous nasal cartilage tissues were 
engineered for the treatment of full-thickness 
cartilage defects in the knee joint, providing 
evidence of engraftment of the graft within the 
defect site3. While the Phase I trials have 
demonstrated the safety and feasibility of the 
approach, a multicenter Phase II clinical trial is 
being initiated to finally prove efficacy of the 
tissue-engineered nasal cartilage grafts for the 
treatment of cartilage lesions in the knee 
[www.biochip-h2020.eu]. In parallel, innovative 
bioreactor-based platforms that automate, 
standardize, and scale up the production process 
are developed with the aim to foster exploitation 
of tissue-engineered products for widespread 
clinical use4 [www.biocomet.eu]. 
DISCUSSION & CONCLUSIONS:  
The translation of research scale production 
models into clinically applicable manufacturing 
designs that are compliant with regulatory 
requirements (e.g., GMP, GDP, GCP) and 
economically sustainable poses major challenges 
to bring tissue-engineered products into routine 
clinical practice. Successes, struggles and setbacks 
have characterized our way and will be discussed: 
from the bench to clinical trials, from single to 
multiple centres in Europe with centralized GMP 
production, from conventional to automated 
manufacturing. Close collaboration among 
clinicians, academic institutions, industrial 
partners, and regulatory agencies is being crucial 
to expedite the route to successful clinical transla-
tion of engineered tissue products. 
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